Solutions and aerosols of metal-containing compounds

• US 20030203046A1
• Filed: 02/12/2003
• Published: 10/30/2003
• Est. Priority Date: 07/27/2000
• Status: Active Grant

• Current Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Original Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Inventors: Naylor, Antony G., Lam, Kan, Wright, John B., Gillis, Scott H., Schechter, Paul, Burrell, Robert E., Moxham, Peter H., Yin, Hua Qing
• Granted Patent: US 7,078,060 B2
• Time in Patent Office: Days
• US Class Current: 424/618
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 2800/413 Nanosized, i.e. having sizes below 100 nm
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/242 Gold; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 33/38 Silver; Compounds thereof
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 8/19 containing inorganic ingredients
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/1682 Processes
• CPC Class Codes: A61K 9/51 Nanocapsules; Nanoparticles; nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61L 15/46 : Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
• CPC Class Codes: A61L 17/145 : Coating
• CPC Class Codes: A61L 2300/104 : Silver, e.g. silver sulfadiazine
• CPC Class Codes: A61L 2300/404 : Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/606 : Coatings
• CPC Class Codes: A61L 2300/63 : Crystals
• CPC Class Codes: A61L 27/30 : Inorganic materials
• CPC Class Codes: A61L 29/10 : Inorganic materials
• CPC Class Codes: A61L 31/082 : Inorganic materials
• CPC Class Codes: A61P 17/00 : Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 : for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61Q 17/005 : Antimicrobial preparations
• CPC Class Codes: A61Q 19/00 : Preparations for care of the skin
• CPC Class Codes: B82Y 5/00 : Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Solutions and aerosols of metal-containing compounds are disclosed. Methods of preparing and using the solutions and aerosols, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.

Claims

1. A method of treating a subject having a condition, comprising:

contacting an area of the subject having the condition with a solution containing an atomically disordered, nanocrystalline metal-containing compound.

2. The method of claim 1, wherein the metal-containing compound is selected from the group consisting of metals and alloys.

3. The method of claim 1, wherein the metal-containing compound is selected from the group consisting of metal oxides, metal nitrides, metal borides, metal halides and metal hydrides.

4. The method of claim 1, wherein the metal-containing compound comprises a metal selected from the group consisting of silver, gold, platinum and palladium.

5. The method of claim 1, wherein the metal-containing compound comprises silver.

6. The method of claim 1, wherein the metal-containing compound comprises an ionic compound.

7. The method of claim 1, wherein the metal-containing compound comprises atoms, molecules or clusters.

8. The method of claim 1, wherein the metal-containing compound comprises an antimicrobial compound.

9. The method of claim 1, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

10. The method of claim 1, wherein the condition is selected from skin conditions and integument conditions.

11. The method of claim 10, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, noncancerous growths, idiopathic conditions, noncancerous growths, and cancerous conditions.

12. The method of claim 10, wherein the condition is selected from the group consisting of a bum, eczema, erythroderma, an insect bite, mycosis fungoides, pyoderma gangrenosum, eythrema multiforme, rosacea, onychomyocosis, acne, psoriasis, Reiter'"'"'s syndrome, pityriasis rubra pilaris, hyperpigmentation, vitiligo, hypertropic scarring, keloid, lichen plainus, age related skin disorders and hyperproliferative variants of the disorders of keratinization.

13. The method of claim 1, wherein the condition comprises a respiratory condition.

14. The method of claim 13, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral respiratory conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

15. The method of claim 13, wherein the respiratory condition is selected from the group consisting of asthma, emphysema, bronchitis, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary fibrosis, pulmonary atelectasis, tuberculosis, pneumonia, sinusitis, pharyngitis, mucositis, stomatitis, chronic obstructive pulmonary disease, bronchiectasis, lupus pneumonitis and cystic fibrosis.

16. The method of claim 1, wherein the condition comprises a musculo-skeletal condition.

17. The method of claim 16, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

18. The method of claim 16, wherein the musculo-skeletal condition is selected from the group consisting of tendonitis, osteomyelitis, fibromyalgia, bursitis and arthritis.

19. The method of claim 1, wherein the condition comprises a circulatory condition.

20. The method of claim 19, wherein the circulatory condition is selected from the group consisting of microbial conditions, inflammatory conditions, fungal circulatory conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

21. The method of claim 19, wherein the circulatory condition is selected from the group consisting of arteriosclerosis, septicemia, leukemia, ischemic vascular disease, lymphangitis and atherosclerosis.

22. The method of claim 1, wherein the condition comprises cancer.

23. The method of claim 22, wherein the cancer is selected from the group consisting of tumors and hematologic malignancies.

24. The method of claim 1, wherein the area of the subject is selected from the group consisting of a hyperplastic tissue, a tumor tissue and a cancerous lesion.

25. The method of claim 24, wherein the method induces apoptosis at the area of the subject.

26. The method of claim 24, wherein the method modulates matrix metalloproteinases at the area of the subject.

27. The method of claim 1, wherein the condition is selected from mucosal conditions and serosal conditions.

28. The method of claim 27, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

29. The method of claim 27, wherein the condition is selected from the group consisting of pericarditis, Bowen'"'"'s disease, stomatitis, prostatitis, sinusitis, digestive disorders, toxic epidermal necrolysis syndrome, Stevens Johnson syndrome, cystic fibrosis, bronchitis, pneumonia, pharyngitis, common cold, ear infections, sore throat, sexually transmitted diseases, inflammatory bowel disease, colitis, hemorrhoids, thrush, dental conditions, oral conditions, conjunctivitis, and periodontal conditions.

30. The method of claim 1, wherein the solution contains at least about 0.001 weight percent of the metal-containing compound.

31. The method of claim 30, wherein the solution contains about 10 weight percent or less of the metal-containing compound.

32. The method of claim 1, further comprising forming the solution containing the metal-containing compound,

wherein the solution containing the metal-containing compound is contacted with the area of the subject having the condition within about one minute or less of formation of the solution containing the compound metal-containing.

33. The method of claim 1, further comprising forming the solution containing the metal-containing compound,

wherein a period of at least about 1.5 minutes passes between when the solution containing the metal-containing compound is formed and the solution containing the metal-containing compound is contacted with the area of the subject having the condition.

34. The method of claim 1, wherein the solution further comprises a solvent.

35. The method of claim 1, further comprising forming the solution by

combining a powder of the metal-containing compound in a solvent.

36. The method of claim 1, further comprising forming the solution by disposing an article containing the metal-containing compound in a solvent, the article comprising a substrate having a coating of the metal-containing compound disposed thereon.

37. The method of claim 1, further comprising forming the solution into an aerosol.

38. The method of claim 37, further comprising inhaling the aerosol.

39. The method of claim 1, wherein contacting the area of the subject having the condition includes injecting the solution into the subject.

40. The method of claim 39, wherein the solution is injected with a needleless injector.

41. The method of claim 39, wherein the solution is injected with a needle.

42. A solution, comprising:

an atomically disordered, nanocrystalline metal-containing compound; and

a solvent for the metal-containing compound, the metal-containing compound being at least partially dissolved in the solvent.

43. The solution of claim 42, wherein the metal-containing compound is selected from the group consisting of metals and alloys.

44. The solution of claim 42, wherein the metal-containing compound is selected from the group consisting of metal oxides, metal nitrides, metal borides, metal halides and metal hydrides.

45. The solution of claim 42, wherein the metal-containing compound comprises a metal selected from the group consisting of silver, gold, platinum and palladium.

46. The solution of claim 42, wherein the metal-containing compound comprises silver.

47. The solution of claim 42, wherein the metal-containing compound comprises an ionic compound.

48. The solution of claim 42, wherein the metal-containing compound comprises atoms, molecules or clusters.

49. The solution of claim 42, wherein the metal-containing compound comprises an antimicrobial compound.

50. The solution of claim 42, wherein the solution contains at least about 0.001 weight percent of the metal-containing compound.

51. The solution of claim 50, wherein the solution contains about 10 weight percent or less of the metal-containing compound.

52. The solution of claim 42, wherein the solvent comprises water.

53. An aerosol comprising a nanocrystalline, metal-containing compound.

54. The aerosol of claim 53, wherein the metal-containing compound is selected from the group consisting of metals and alloys.

55. The aerosol of claim 53, wherein the metal-containing compound is selected from the group consisting of metal oxides, metal nitrides, metal borides, metal halides and metal hydrides.

56. The aerosol of claim 53, wherein the metal-containing compound comprises a metal selected from the group consisting of silver, gold, platinum and palladium.

57. The aerosol of claim 53, wherein the metal-containing compound comprises silver.

58. The aerosol of claim 53, wherein the metal-containing compound comprises an ionic compound.

59. The aerosol of claim 53, wherein the metal-containing compound is an atomically disordered compound.

60. The aerosol of claim 53, wherein the metal-containing compound comprises atoms, molecules or clusters.

61. The aerosol of claim 53, wherein the metal-containing compound comprises an antimicrobial compound.

62. An aerosol comprising an atomically disordered, metal-containing compound.

63. The aerosol of claim 62, wherein the metal-containing compound is selected from the group consisting of metals and alloys.

64. The aerosol of claim 62, wherein the metal-containing compound is selected from the group consisting of metal oxides, metal nitrides, metal borides, metal halides and metal hydrides.

65. The aerosol of claim 62, wherein the metal-containing compound comprises a metal selected from the group consisting of silver, gold, platinum and palladium.

66. The aerosol of claim 62, wherein the metal-containing compound comprises silver.

67. The aerosol of claim 62, wherein the metal-containing compound comprises an ionic compound.

68. The aerosol of claim 62, wherein the metal-containing compound comprises atoms, molecules or clusters.

69. The aerosol of claim 62, wherein the metal-containing compound comprises an antimicrobial compound.

70. A method of treating a subject having a condition, comprising:

contacting an area of the subject having the condition with an atomically disordered, crystalline metal-containing compound by injecting a solution containing the nanocrystalline metal-containing compound.

71. The method of claim 70, wherein the metal-containing compound is selected from the group consisting of metals and alloys.

72. The method of claim 70, wherein the metal-containing compound is selected from the group consisting of metal oxides, metal nitrides, metal borides, metal halides and metal hydrides.

73. The method of claim 70, wherein the metal-containing compound comprises a metal selected from the group consisting of silver, gold, platinum and palladium.

74. The method of claim 70, wherein the metal-containing compound comprises silver.

75. The method of claim 70, wherein the metal-containing compound comprises an ionic compound.

76. The method of claim 70, wherein the metal-containing compound comprises atoms, molecules or clusters.

77. The method of claim 70, wherein the metal-containing compound comprises an antimicrobial compound.